management

J. Donald deBethizy PhD
President & Chief Executive Officer

Donald deBethizy co-founded Targacept, Inc. and served as its President and CEO for 15 years. He led Targacept’s private and public financings totaling approximately $330 million including the company’s Initial Public Offering on Nasdaq in 2006. In addition, he played a key role in developing Targacept's business relationships with GSK, AstraZeneca, Aventis and Dr. Falk Pharma, all of which together generated non-dilutive revenues of over $300 million.

Henrik Stage, MSc
Chief Financial Officer & EVP Corporate Development

Henrik Stage has a strong and diverse background from senior executive positions within the biotech and industrial industries where he has been responsible for strategic planning, business development, finance, operations and investor relations. Henrik previously held senior executive positions at Carlsberg, FLS Industries, and Hempel and Hardy International in Denmark, USA, Canada and Vietnam. He has a background in finance and received his master’s degree in finance at the Copenhagen Business School, Denmark. Mr. Stage has been with Santaris Pharma since 2004.

Henrik Ørum MSc PhD
Chief Scientific Officer & VP Business Development

Henrik Ørum is a co-founder of Cureon A/S, which merged with Pantheco A/S to form Santaris Pharma. He was previously Director R&D and CSO at PNA Diagnostics A/S (formerly a subsidiary of Boehringer Mannheim and Hoffmann-La Roche) with responsibilities for the overall scientific and business strategy and intellectual property rights of the company.

Henrik Ørum is co-founder and previous board member of Exiqon A/S and co-founder of Cascade Aps. He holds a MSc in molecular biology from the Technical University of Copenhagen, a PhD in molecular biology from the Medical University of Copenhagen and conducted postdoctoral studies at the Copenhagen Royal School of Pharmacy. Dr. Ørum has extensive operational and strategic experience in all aspects of starting, developing, and managing biotech companies. He is the author and co-author of more than 40 scientific publications and books and has been issued several patents. Dr. Ørum is often invited to speak at scientific and biotech conferences and symposia.

Michael R. Hodges, MD
Chief Medical Officer & VP

Michael R. Hodges, M.D., MBBS, BSc., MRCP, has 20 years of biopharmaceutical development experience in both large pharmaceutical and biotechnology companies across a broad range of therapeutic areas, including infectious disease, oncology, respiratory disease and dyslipidemia. His career has included working on the development programs for the following commercial products: Vfend®, Diflucan®, Zithromax®, Tarceva® and Viagra®. Prior to joining Santaris Pharma A/S, Dr. Hodges served as Chief Medical Officer for Altair Therapeutics Inc., a respiratory RNA therapeutic platform company. He practiced internal medicine at several University of London hospitals and received board certification in internal medicine. Dr. Hodges received his undergraduate degree in Pharmacology from Kings College and medical degree at the Westminster Medical School, University of London, UK. He currently serves on the Board of Directors of F2G, a biotechnology company focused on developing anti-fungal drugs.

Troels Koch, PhD
Chief Technology Officer & VP Research

Troels Koch is a co-founder of Cureon A/S, which merged with Pantheco A/S to form Santaris Pharma. He was previously Director of Chemistry & Operations at PNA Diagnostics A/S (a former subsidiary of Boehringer Mannheim and Hoffmann-La Roche). He is also a co-founder of Exiqon A/S. Dr. Koch has worked intensively with DNA, LNA, and PNA oligonucleotide technologies in the diagnostics and pharmaceutical industries. He has substantial experience in managing R&D activities, intellectual property rights and quality systems in biotech companies. He is the author and co-author of more than 60 scientific publications and books and 25 patents, and he is often invited to speak at scientific conferences and symposiums. He holds a MSc and a PhD in bioorganic chemistry obtained from the University of Copenhagen/University of Illinois.

Bo Rode Hansen, MSc, PhD
VP, Alliance Management & Partnered Drug Discovery

Bo Rode Hansen has worked for the last 12 years in the pharmaceutical biotech industry serving in different positions at Cureon A/S and Santaris Pharma A/S. He has significant senior level experience in all aspects of the R&D value chain and is experienced in the business space of RNA targeted therapeutics. He has contributed on both strategic and operational levels of managing alliances and drug discovery projects, and served as leader for both internal research projects, people and line management. He is author or coauthor of more than 20 papers in peer reviewed scientific journals and is an inventor of 15 base patents. He is frequently invited to speak at international scientific conferences.

Dr. Rode Hansen’s educational merits include an executive MBA from Henley Business School. His academic credentials include a PhD in pharmaceutical sciences and a MSc in Biochemistry from Copenhagen University including a research exchange program at the University of Pavia in Italy.